Videos

Matthew Steven Davids, MD, MMSc, on the Venetoclax, R-EPOCH Combo for Richter’s Syndrome

July 26th 2020

The CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.

pre- and post-genetic testing online education

Kelly Morgan, MS, CGC, on Findings from the BFOR Trial in Genetic Testing

ByKelly Morgan, MS, CGC

July 25th 2020

The MSK expert discussed how pre- and post-genetic testing online education made patients more knowledgeable about genetic testing.

Scott Tykodi, MD, PhD, on Takeaways from KEYNOTE-427 in Renal Cell Carcinoma

ByScott S. Tykodi, MD, PhD

July 24th 2020

The Seattle Cancer Care Alliance expert discusses key takeaways from cohort a of the KEYTRUDA-427 study, evaluating pembrolizumab monotherapy in patients with clear cell renal cell carcinoma.

Sameera Kumar, MD, on Treating Patients with NSCLC During the COVID-19 Pandemic

ByHannah Slater

July 24th 2020

The expert from the Fox Chase Cancer Center discussed a paper recently published regarding alternative multidisciplinary management options for patients with NSCLC during the COVID-19 pandemic.

Courtney DiNardo, MD, on Combination Regimens Findings in IDH1-Positive AML

ByCourtney DiNardo, MD

July 23rd 2020

The MD Anderson Cancer Center expert spoke about the efficacy of ivosenidib plus venetoclax, with or without azacytidine, in patients with IDH1-mutated acute myeloid leukemia.

Karen H. Lu, MD, on Next Steps in Evaluating Genetic Testing in Underrepresented Minorities

ByKaren H. Lu, MD

July 22nd 2020

The MD Anderson Cancer Center expert discussed further research in delivering online accessible genetic testing.

Benjamin Levy, MD, on Colon Cancer Screening During the COVID-19 Pandemic

ByHannah Slater

July 21st 2020

The board-certified gastroenterologist discussed the lack of screenings being conducted due to the COVID-19 pandemic, and how many physicians have tried to circumvent this issue.

Kelly Morgan, MS, CGC, on Pre- and Post-Test Online Education for the Ashkenazi Jewish BRCA Mutation

ByKelly Morgan, MS, CGC

July 20th 2020

The MSK expert discussed what pre- and post-test online education consists of in testing for the Ashkenazi Jewish BRCA mutations in the US healthcare system.

Petros Grivas, MD, PhD, on the Implications of the COVID-19 and Cancer Consortium

ByPetros Grivas, MD, PhD

July 19th 2020

The expert oncologist spoke about the conclusions drawn from the COVID-19 and Cancer Consortium, as well as the importance of prognostic biomarkers.

Parameswaran Hari, MD, MRCP, Discusses Second Malignancies and Second Transplants in Multiple Myeloma Treatment

ByParameswaran Hari, MD, MRCP

July 18th 2020

Parameswaran Hari, MD, MRCP, discussed second malignancies and second transplants for patients who stopped versus continued lenalidomide maintenance therapy to treat multiple myeloma from a follow-up trial presented at the 2020 ASCO Virtual Scientific Program.

Ursula A. Matulonis, MD, on the KEYNOTE-100 Study Design

ByUrsula A. Matulonis, MD

July 17th 2020

The expert from Dana-Farber Cancer Institute discussed the study design and inclusion criteria for this study of pembrolizumab in patients with advanced recurrent ovarian cancer.

Marlene Camacho-Rivera, MS, MPH, ScD, on Hispanic Trusted Cancer Information Resources

ByHannah Slater

July 17th 2020

The expert from the CUNY School of Medicine spoke about a recent study which indicated that Hispanic adults trust a wide variety of health information sources, suggesting the need for targeted information.

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN Trial

ByConstantine Si Lun Tam, MD, MBBS, FRACP, FRCPA

July 16th 2020

The trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.

Karen H. Lu, MD, on Key Takeaways from Online Genetic Testing

ByKaren H. Lu, MD

July 16th 2020

The MD Anderson Cancer Center expert spoke about the key takeaways from a trial designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.

ASCO Expert on the Analysis of Autologous Stem Cell Transplant in Relapsed DLBCL

ByNirav Niranjan Shah, MD

July 15th 2020

Nirav Niranjan Shah, MD, discussed the use of autologous transplantation in patients with relapsed, chemosensitive DLBCL after the introduction of CAR T-cells.

Caron A. Jacobson, MD, on What Patients Should Know About the Phase 2 ZUMA-5 Study

ByCaron A. Jacobson, MD

July 14th 2020

The expert in hematology discussed what patients should know about the study, which evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Xin Wei Wang, PhD, on New Blood Test Able to Identify Those Likely to Develop HCC

ByHannah Slater

July 14th 2020

The co-leader of the NCI Center for Cancer Research Liver Cancer Program discussed the clinical utility of the blood test and how it could potentially change liver cancer diagnoses moving forward.

Andres Poveda, MD, on the Implications of the Phase 3 SOLO2/ENGOT-ov21 Trial

ByAndres Poveda, MD

July 13th 2020

The expert in ovarian cancer indicated that treatment with the studied maintenance olaparib tablets could aid patients in having a more regular lifestyle.

Scott Tykodi, MD, PhD, Discusses Biomarker Detection, Analysis in RCC

ByScott S. Tykodi, MD, PhD

July 13th 2020

The Seattle Cancer Care Alliance Expert offered background on cohort A of the KEYNOTE-427 trial.

John Kuruvilla, MD, Discusses Toxicities Observed in the Phase 3 KEYNOTE-204 Study

ByJohn Kuruvilla, MD

July 12th 2020

The expert in hematology highlighted the toxicities reported in this trial and explained the differences observed between the 2 drugs studied.

Matthew Steven Davids, MD, MMSc on Venetoclax Plus R-EPOCH in Hematologic Cancers

ByMatthew Steven Davids, MD, MMSc

July 11th 2020

The chronic lymphocytic leukemia expert spoke about the possible use of venetoclax plus dose-adjusted R-EPOCH in various hematologic patient populations.

Robert L. Coleman, MD, on Methods of the GOG Study in Ovarian Cancer

ByRobert L. Coleman, MD, FACOG, FACS

July 10th 2020

The expert discussed study methods from the NRG Oncology/Gynecologic Oncology Group (GOG) study presented at the 2020 ASCO Virtual Program.

Jun J. Mao, MD, MSCE, on Non-Pharmacological Pain Management in Cancer Survivors

ByJun J. Mao, MD, MSCE

July 10th 2020

At the 2020 ASCO Virtual Program, Jun J. Mao, MD, MSCE, presented a study designed to evaluate the comparative effectiveness of electro-acupuncture and auricular acupuncture versus usual care in managing pain in cancer survivors.

Petros Grivas, MD, PhD, on Future Updates to the COVID-19 and Cancer Consortium

ByPetros Grivas, MD, PhD

July 9th 2020

Data from the registry suggested that in patients with cancer and COVID-19, cancer that is progressing was independently associated with an increased risk of death.

Fumiko Chino, MD, on Next Steps in Evaluating Medicare’s Impact on Cancer Mortality Rates

ByFumiko Chino, MD

July 8th 2020

The expert explained how states that expanded Medicaid coverage saw a steeper decline in cancer mortality rates, and next steps for further evaluation.

Courtney DiNardo, MD, on Study Methods Evaluating a Doublet, Triplet Regimens in AML

ByCourtney DiNardo, MD

July 8th 2020

At the 2020 ASCO Virtual Program, Courtney DiNardo, MD, presented on a study of the combination therapy consisting of ivosenidib plus venetoclax with or without azacytidine patients with IDH1-mutated acute myeloid leukemia.

Karen H. Lu, MD, on Genetic Testing From Patients’ Living Rooms

ByKaren H. Lu, MD

July 6th 2020

At the 2020 ASCO Virtual Scientific Program, Karen H. Lu, MD, presented on findings from the MAGENTA trial, designed to test whether pre and/or post-test genetic counseling is needed to optimally deliver online accessible genetic testing.

Petros Grivas, MD, PhD, on Advice for Patients with Cancer During the COVID-19 Pandemic

ByPetros Grivas, MD, PhD

July 5th 2020

The expert oncologist discussed the findings of the COVID-19 and Cancer Consortium and how the results of the consortium should inform conversations with patients with cancer.

Karen H. Lu, MD, on Delivering Online, Accessible Genetic Testing

ByKaren H. Lu, MD

July 4th 2020

The expert discussed study methods and results from the MAGENTA trial evaluating pre and/or post-test genetic counseling.

Michael J. Morris, MD, on Future Directions of PSMA Imaging in Prostate Cancer

ByMichael J. Morris, MD

July 3rd 2020

Results of phase 3 CONDOR study could have a far-reaching impact on patients with prostate cancer.

Videos

Matthew Steven Davids, MD, MMSc, on the Venetoclax, R-EPOCH Combo for Richter’s Syndrome

Kelly Morgan, MS, CGC, on Findings from the BFOR Trial in Genetic Testing

Scott Tykodi, MD, PhD, on Takeaways from KEYNOTE-427 in Renal Cell Carcinoma

Sameera Kumar, MD, on Treating Patients with NSCLC During the COVID-19 Pandemic

Courtney DiNardo, MD, on Combination Regimens Findings in IDH1-Positive AML

Karen H. Lu, MD, on Next Steps in Evaluating Genetic Testing in Underrepresented Minorities

Benjamin Levy, MD, on Colon Cancer Screening During the COVID-19 Pandemic

Kelly Morgan, MS, CGC, on Pre- and Post-Test Online Education for the Ashkenazi Jewish BRCA Mutation

Petros Grivas, MD, PhD, on the Implications of the COVID-19 and Cancer Consortium

Parameswaran Hari, MD, MRCP, Discusses Second Malignancies and Second Transplants in Multiple Myeloma Treatment

Ursula A. Matulonis, MD, on the KEYNOTE-100 Study Design

Marlene Camacho-Rivera, MS, MPH, ScD, on Hispanic Trusted Cancer Information Resources

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN Trial

Karen H. Lu, MD, on Key Takeaways from Online Genetic Testing

ASCO Expert on the Analysis of Autologous Stem Cell Transplant in Relapsed DLBCL

Caron A. Jacobson, MD, on What Patients Should Know About the Phase 2 ZUMA-5 Study

Xin Wei Wang, PhD, on New Blood Test Able to Identify Those Likely to Develop HCC

Andres Poveda, MD, on the Implications of the Phase 3 SOLO2/ENGOT-ov21 Trial

Scott Tykodi, MD, PhD, Discusses Biomarker Detection, Analysis in RCC

John Kuruvilla, MD, Discusses Toxicities Observed in the Phase 3 KEYNOTE-204 Study

Matthew Steven Davids, MD, MMSc on Venetoclax Plus R-EPOCH in Hematologic Cancers

Robert L. Coleman, MD, on Methods of the GOG Study in Ovarian Cancer

Jun J. Mao, MD, MSCE, on Non-Pharmacological Pain Management in Cancer Survivors

Petros Grivas, MD, PhD, on Future Updates to the COVID-19 and Cancer Consortium

Fumiko Chino, MD, on Next Steps in Evaluating Medicare’s Impact on Cancer Mortality Rates

Courtney DiNardo, MD, on Study Methods Evaluating a Doublet, Triplet Regimens in AML

Karen H. Lu, MD, on Genetic Testing From Patients’ Living Rooms

Petros Grivas, MD, PhD, on Advice for Patients with Cancer During the COVID-19 Pandemic

Karen H. Lu, MD, on Delivering Online, Accessible Genetic Testing

Michael J. Morris, MD, on Future Directions of PSMA Imaging in Prostate Cancer

Trending on CancerNetwork

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology